import type { ReportEntry } from '@/data/healthcareReportTypes';

const SLUG = 'uae-digital-health-market-report';

/**
 * Curated copy for the UAE digital health programmatic report.
 * Market sizing: BioNixus market analysis, 2026 (aligned with factRegistry: ~USD 96M 2026 → ~USD 168M 2030, ~17.5% CAGR).
 * Detail: Malaffi (Abu Dhabi), Nabidh (Dubai), Riayati (federal) HIEs, MOHAP/DHA/DOH, SaMD; figures attributed to BioNixus analysis.
 */
type OverrideCopy = Partial<ReportEntry> & Pick<ReportEntry, 'slug'>;

export const UAE_DIGITAL_HEALTH_COPY: OverrideCopy = {
  slug: SLUG,
  title: 'UAE Digital Health Market Report 2026',
  metaTitle: 'UAE Digital Health Market Report 2026 | BioNixus',
  metaDescription:
    'UAE digital health market ~USD 96M in 2026 (BioNixus analysis), ~17.5% CAGR: Malaffi & Nabidh health information exchanges, MOHAP/DHA/DOH, telehealth, AI diagnostics, SaMD regulation—decision-ready Gulf intelligence.',
  heroLead:
    'This briefing reads UAE digital health through its data backbone: mandatory health-information exchanges—Malaffi in Abu Dhabi, Nabidh in Dubai, and the federal Riayati—plus emirate smart-health strategies, where integration with these platforms, not the technology itself, decides whether a digital solution scales across the country.',
  summaryPara1:
    'The UAE is a digital-health frontrunner, distinguished by mandatory, emirate-level health-information exchanges that most markets lack. BioNixus sizes the market at roughly USD 96 million in 2026, advancing toward about USD 168 million by 2030 at roughly 17.5% CAGR. Abu Dhabi’s Malaffi and Dubai’s Nabidh exchanges, with the federal Riayati layer, connect providers and create both an integration requirement and an opportunity; DHA and DOH smart-health strategies, telehealth, AI diagnostics, and a medical-tourism digital front-end round out demand. MOHAP, DHA, and DOH govern software-as-a-medical-device and AI-device pathways. The binding constraints are emirate-specific integration, data governance, and clinical-workflow fit rather than technology novelty. Sizing reflects BioNixus market analysis, 2026.',
  summaryPara2:
    'Use this report with the [UAE healthcare market report](/uae-healthcare-market-report) for macro context, the [UAE medical devices market report](/market-reports/uae-medical-devices-market-report) for the SaMD and connected-device overlap, the [GCC digital health market report](/market-reports/gcc-digital-health-market-report) for Gulf-wide benchmarking, the [Saudi Arabia digital health market report](/market-reports/saudi-arabia-digital-health-market-report) for the contrasting national-platform model, [digital-health research](/healthcare-market-research/therapy/digital-health) for programme design, and the [healthcare market research hub](/healthcare-market-research) to scope bilingual fieldwork.',
  marketAccessNotes:
    'Mandatory health-information exchanges—Malaffi (Abu Dhabi), Nabidh (Dubai), and federal Riayati—as integration requirements and data backbones; DHA and DOH smart-health strategies and emirate-specific procurement; MOHAP/DHA/DOH software-as-a-medical-device and AI-device classification shaping the regulatory pathway; data-residency, interoperability, and HIE-connectivity requirements gating scale; telehealth, AI diagnostics, and remote monitoring as growth segments; medical-tourism digital front-ends and a large private sector adding commercial routes beyond government',
  fieldIntelligenceParagraph:
    'BioNixus field programmes treat UAE digital health as an integration-first, emirate-segmented market. The decisive questions are whether a solution connects to the relevant HIE (Malaffi, Nabidh, or via Riayati), satisfies MOHAP/DHA/DOH SaMD or AI classification where it is a medical device, meets data-residency and interoperability rules, and earns clinician adoption inside workflows that differ between Abu Dhabi, Dubai, and the northern emirates. We pair bilingual clinician and administrator quantitative work with health-IT-leader, payer, and procurement depth, and we map the pilot-to-scale gap and the private-versus-government routes to market. We also distinguish solutions regulated as medical devices from wellness or pure-IT tools, because that changes the pathway. KOL maps follow real informatics, HIE, and clinical-champion influence rather than title lists.',
  commercialOutlookParagraph:
    'The outlook to 2030 is high-growth and infrastructure-shaped. Telehealth, AI diagnostics, remote monitoring, and clinical decision support will expand as HIEs mature and emirate smart-health strategies advance, but winners will integrate with Malaffi, Nabidh, and Riayati, clear SaMD/AI requirements where applicable, and prove workflow value. The large private sector and medical-tourism front-end offer commercial routes beyond government procurement. Manufacturers and digital-health vendors should plan emirate-specific integration and regulatory strategies and treat HIE connectivity as table stakes. Leadership should stress-test scale potential against HIE integration and emirate procurement before committing investment, since fragmentation across emirates is the main rate limiter.',
  methodologyParagraph:
    'Methodology combines BioNixus market analysis for sizing and CAGR bands with structured desk review of MOHAP, DHA, DOH, Malaffi, Nabidh, and Riayati public guidance and SaMD/AI device frameworks, plus primary modules—clinician, administrator, and health-IT-leader interviews and adoption surveys where data is available. Because SaMD/AI classification, HIE interoperability standards, and emirate procurement models change on short cycles, regulatory and access statements should be revalidated before launch decisions. Figures are planning inputs rather than audited financials. Outputs are built for market access, digital-health commercial, and medical-affairs leadership and do not constitute regulatory or legal advice.',
  faqs: [
    {
      question: 'How large is the UAE digital health market in 2026?',
      answer:
        'BioNixus market analysis sizes the UAE digital-health market at roughly USD 96 million in 2026, advancing toward about USD 168 million by 2030 at roughly 17.5% CAGR — one of the faster-growing healthcare segments in the Gulf. The UAE is a regional frontrunner, distinguished by mandatory health-information exchanges (Malaffi in Abu Dhabi, Nabidh in Dubai, and the federal Riayati layer), near-universal insurance, strong telehealth adoption, and early AI-diagnostics deployment. Growth concentrates in telehealth, remote monitoring, AI-enabled imaging, and exchange-connected patient applications rather than spreading evenly across the category. Treat the headline figure as a planning band, not an audited total: BioNixus pairs it with clinician adoption and procurement signals so teams size the integration-ready opportunity. For Gulf-wide context use the GCC digital health report, and the Saudi Arabia report for the contrasting national-platform model.',
    },
    {
      question: 'What role do Malaffi, Nabidh, and Riayati play in UAE digital health?',
      answer:
        'These mandatory health-information exchanges are the data backbone of UAE digital health: Malaffi connects Abu Dhabi providers, Nabidh connects Dubai, and the federal Riayati layer links the system nationally. For digital-health vendors, connectivity to the relevant exchange is effectively a precondition to scale — a solution that cannot exchange records with the emirate platform tends to stall at pilot regardless of clinical merit. Requirements differ by emirate in data standards, onboarding, and procurement ownership, so a single national integration plan rarely works. BioNixus maps these integration requirements, the technical onboarding path, and the procurement owners for each platform, so commercial teams design around the data backbone from the outset rather than discovering interoperability gaps only after a pilot has been funded and clinical champions recruited.',
    },
    {
      question: 'How is software-as-a-medical-device regulated in the UAE?',
      answer:
        'MOHAP provides federal oversight while DHA and DOH add emirate-level requirements, so the first question for any solution is classification: software regulated as a medical device (SaMD) or an AI-enabled device follows a defined regulatory pathway, whereas wellness and pure-IT tools follow lighter routes. Getting this wrong delays launch or invites enforcement. Beyond classification, scaling depends on health-information-exchange connectivity, data-residency and interoperability rules, and emirate-specific procurement cycles. BioNixus helps teams clarify SaMD or AI classification first, then sequence Malaffi, Nabidh, and Riayati integration with emirate procurement so regulatory and commercial workstreams run in parallel. Because classification rules and AI-device frameworks are revised on short cycles, we recommend revalidating the pathway immediately before any launch or investment decision rather than relying on prior-year guidance.',
    },
    {
      question: 'How does UAE digital health differ from Saudi Arabia?',
      answer:
        'Saudi Arabia runs a centralized, national, government-led model — Seha Virtual Hospital, the Sehhaty citizen app, and a national electronic health record under Vision 2030 — so vendors integrate once at national level. The UAE is emirate-federated: Abu Dhabi (Malaffi, DOH) and Dubai (Nabidh, DHA) operate distinct platforms and smart-health strategies beneath a federal layer, alongside a larger private and medical-tourism sector. The practical consequence is that UAE entrants face multiple emirate-specific integration and procurement tracks where Saudi entrants face one national platform. Neither is inherently easier — Saudi concentrates approval risk centrally, the UAE distributes it across emirates. BioNixus maps both models side by side so cross-Gulf digital-health strategies budget realistically for integration effort and avoid assuming a Saudi national playbook transfers directly to the UAE.',
    },
    {
      question: 'Which digital health segments are growing fastest in the UAE?',
      answer:
        'Telehealth and virtual care, AI-enabled diagnostics and clinical decision support, remote patient monitoring, and patient-engagement applications connected to the emirate health-information exchanges are the fastest-growing segments. The medical-tourism digital front-end — online booking, records access, and remote follow-up for international patients — is a distinctive UAE opportunity that few other Gulf markets can match at scale. Chronic-disease management tools tied to the high diabetes and cardiovascular burden are also expanding as insurers begin to reward measurable outcomes. Across all of these, the common success factor is the same: solutions that integrate with Malaffi, Nabidh, or Riayati and meet data-governance expectations are advantaged, while standalone tools that ignore the data backbone struggle to move beyond isolated pilots regardless of their clinical sophistication.',
    },
    {
      question: 'How does BioNixus help digital health teams win in the UAE?',
      answer:
        'BioNixus designs bilingual (Arabic–English) UAE digital-health programmes: clinician, administrator, and health-IT-leader adoption studies, HIE-integration and procurement mapping across Malaffi, Nabidh, and Riayati, MOHAP/DHA/DOH SaMD/AI pathway research, and KOL mapping tied to real informatics and clinical-champion influence. Deliverables align to launch, integration, or procurement milestones and connect UAE findings to GCC and global benchmarks (notably the Saudi national-platform model) only when a comparator truly informs governance. Typical outputs include emirate integration archetypes, pilot-to-scale risk maps, regulatory-pathway analysis, and committee-ready executive summaries. We treat health-information-exchange connectivity as table stakes in every plan, because a solution that cannot integrate with Malaffi, Nabidh, or Riayati rarely scales beyond pilot. Begin from the healthcare market research hub or request a scoped briefing through the contact page.',
    },
  ],
};
